ACCENDRA HEALTH INC/VA/ — Form 8-K
Filed August 10, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 58/100
What the filing says
Accendra Health reported Q2 2026 continuing operations revenue of $613.2M (down 10% YoY from $681.9M). The company reduced total funded debt by $385M in Q2 through a balance sheet optimization transaction completed in June 2026, with total debt declining from $2,123M (3/31/26) to $1,753M (6/30/26). CEO Edward Pesicka announced his intention to retire by year-end 2026. FY2026 guidance was updated: revenue $2.45B–$2.55B (previously implied higher), adjusted EBITDA $300M–$320M, and free cash flow breakeven to slightly positive. The company incurred a $80M transaction breakage fee from a terminated Rotech acquisition.
Why this rating
Leadership departure plus revenue decline and negative free cash flow are material headwinds. Debt reduction is positive but insufficient offset given 10% revenue drop, negative adjusted net loss, and succession uncertainty.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.